THERAPEUTIC MONITORING OF BUSULFAN IN PEDIATRIC BONE MARROW TRANSPLANTATION
| Autor: | Jerry Stein, Jacob M. Rowe, I. Yaniv, Erica Hoffer, Ronit Elhasid, M. Weyl Ben Arush, N. Krivoy, Arek Tabak |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Bone marrow transplantation medicine.medical_treatment Pharmacokinetics Dose adjustment medicine Animals Humans Tissue Distribution Prospective Studies Dosing Child Prospective cohort study Antineoplastic Agents Alkylating Busulfan Bone Marrow Transplantation Chemotherapy Dose-Response Relationship Drug business.industry Infant Hematology Surgery medicine.anatomical_structure Oncology Area Under Curve Child Preschool Pediatrics Perinatology and Child Health Bone marrow Drug Monitoring business Nuclear medicine medicine.drug |
| Zdroj: | Pediatric Hematology and Oncology. 19:31-37 |
| ISSN: | 1521-0669 0888-0018 |
| DOI: | 10.1080/088800102753356167 |
| Popis: | The aim of this study was to describe busulfan disposition in a pediatric population who underwent bone marrow transplantation (BMT). Busulfan administered dose was 1 mg/kg every 6 h for 4 days. Plasma determinations were performed after the first dosing at 0, 15, 30, 60, 90, 120, 180, 240, 300, and 360 min. A noncompartment analysis model for extravascular absorption was used for the pharmacokinetic analysis. To obtain the area under the concentration-time curve (AUC) within the "therapeutic window" of 1,000-1,200 microM x minutes a busulfan dose adjustment Was performed at the fourth dose. Forty-five busulfan pharmacokinetic analyses were performed in 34 children. Eleven children had their dose adjusted [1.19 +/- 0.14) mg/kg] at the fourth dose and the AUC was monitored at the fifth one. The mean AUC +/- SD after the fifth dose (998.1 +/- 189.2 microM x min) was different (p = .006)from that after the first dose (1 mg/kg) (687.63 +/- 166.43 microM x min). Six children had their first AUC into the "therapeutic window," 17 children had their dose adjusted [1.2 (+/- 0.22) mg/kg], but the "adjusted" AUC was not available. These data suggest that it may be reasonable to recommend a busulfan dose of 1.2 mg/kg to achieve the accepted therapeutic target in children undergoing BMT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|